+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID07077772

Study of Natriuresis-Guided Furosemide Treatment After Cardiac Surgery Using Cardiopulmonary Bypass

Led by Centre Hospitalier Universitaire, Amiens · Updated on 2026-01-21

102

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Fluid overload is a common issue after cardiac surgery, leading to increased risks for patients. Researchers are evaluating whether using a urinary sodium sensor to guide furosemide dosing can improve fluid removal safely and effectively in patients who have undergone cardiac surgery with cardiopulmonary bypass. Participants receive intravenous furosemide starting at 20 mg, with doses adjusted every 6 hours. One group has doses guided by urinary sodium levels using the LAQUAtwin NA-11 device, while the other group has doses adjusted based on clinical evaluation. Urine output is closely monitored every 4 hours, and blood tests are done twice daily to track electrolytes and kidney function. If patients show signs of instability, detailed heart and hemodynamic assessments are performed. During the 48-hour study period after randomization, researchers measure total urine output and natriuresis, along with fluid balance and complications up to 30 days later. The trial monitors safety closely, including any contraindications to furosemide and corrective measures taken. This randomized, open-label trial aims to assess the practical use and effects of natriuresis-guided diuretic treatment after cardiac surgery.

CONDITIONS

Brief Title

Natriuresis-guided Depletion After Cardiac Surgery

Research Team

C

Christophe Beyls, MD, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here